Entero Therapeutics, Inc. financial data

Symbol
ENTO on Nasdaq
Industry
Pharmaceutical Preparations
Location
777 Yamato Road, Suite 502, Boca Raton, FL
State of incorporation
DE
Fiscal year end
December 31
Former names
First Wave BioPharma, Inc. (to 5/16/2024), AzurRx BioPharma, Inc. (to 9/14/2021), BioPharma d'Azur, Inc. (to 4/2/2014)
Latest financial report
10-K/A - Q4 2024 - Apr 9, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 400 % +211%
Debt-to-equity 242 % +108%
Return On Equity -242 % +59.8%
Return On Assets -20.7 % +92.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.77M shares +135%
Common Stock, Shares, Outstanding 4.75M shares +205%
Entity Public Float 3.6M USD -46.3%
Common Stock, Value, Issued 475 USD +204%
Weighted Average Number of Shares Outstanding, Basic 3.43M shares +921%
Weighted Average Number of Shares Outstanding, Diluted 3.43M shares +921%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 904K USD -82%
General and Administrative Expense 14.7M USD +37.1%
Operating Income (Loss) -15.6M USD +0.95%
Nonoperating Income (Expense) 2.25K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.9M USD +44.8%
Income Tax Expense (Benefit) 4.26M USD
Net Income (Loss) Attributable to Parent -18.1M USD -14.3%
Earnings Per Share, Basic -5.33 USD/shares +88.9%
Earnings Per Share, Diluted -5.33 USD/shares +88.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 163K USD -95.6%
Accounts Receivable, after Allowance for Credit Loss, Current 20K USD -28.7%
Assets, Current 83.5M USD +1584%
Property, Plant and Equipment, Net 1.34K USD -95.4%
Operating Lease, Right-of-Use Asset 127K USD -35.1%
Intangible Assets, Net (Excluding Goodwill) 63.4M USD
Goodwill 1.68M USD 0%
Assets 85.4M USD +1141%
Accounts Payable, Current 2.96M USD +434%
Accrued Liabilities, Current 252K USD -69.5%
Liabilities, Current 27.5M USD +779%
Deferred Income Tax Liabilities, Net 571K USD
Operating Lease, Liability, Noncurrent 59K USD -59.8%
Liabilities 27.6M USD +742%
Retained Earnings (Accumulated Deficit) -202M USD -9.8%
Stockholders' Equity Attributable to Parent -3.88M USD -208%
Liabilities and Equity 85.4M USD +1141%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.75M USD -31.7%
Net Cash Provided by (Used in) Financing Activities 3.38M USD -4.74%
Net Cash Provided by (Used in) Investing Activities 88.2K USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 4.75M shares +205%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 185K USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 22K USD +144%
Deferred Tax Assets, Valuation Allowance 37.6M USD +12.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 1.6 pure
Deferred Tax Assets, Gross 39.6M USD +18.2%
Operating Lease, Liability 141K USD -34.3%
Depreciation 14.6K USD -50.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -15.8M USD -17.8%
Lessee, Operating Lease, Liability, to be Paid 149K USD -36.6%
Property, Plant and Equipment, Gross 87.8K USD 0%
Operating Lease, Liability, Current 81.5K USD +21.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 60.6K USD -31.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 88.8K USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.85K USD -58.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 60.6K USD -31.8%
Deferred Tax Assets, Operating Loss Carryforwards 29.6M USD +28.3%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 199M USD +5.63%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 34.2K USD +18%
Deferred Tax Assets, Net of Valuation Allowance 1.9M USD +3865%
Share-based Payment Arrangement, Expense 632K USD -39.3%
Interest Expense 79.7K USD +314%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%